Quantedge Capital’s Coherus Oncology CHRS Stock Holding History

Quantedge Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28,200	Closed	-$364K	–	278
2022 Q1	$364K	Buy	+28,200	New	+$359K	0.11%	155

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Quantedge Capital's CHRS Position: Q2 2022 in Review

Quantedge Capital sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 28,200 shares — an estimated $364K sold.

Quantedge Capital first reported a position in CHRS in Q1 2022 and held it in 1 quarter. The position peaked at $364K in Q1 2022. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

Quantedge Capital reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
Quantedge Capital sold 28,200 Coherus Oncology shares in Q2 2022, an estimated $364K.
Quantedge Capital first reported a position in Coherus Oncology in Q1 2022 and held it in 1 quarter.
Quantedge Capital's Coherus Oncology position peaked at $364K in Q1 2022.
176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Quantedge Capital's 13F filing for Q2 2022, filed 12 Aug 2022.